中国医药
中國醫藥
중국의약
CHINA MEDICINE
2009年
z1期
33-34
,共2页
膀胱癌%羟基喜树碱%干扰素
膀胱癌%羥基喜樹堿%榦擾素
방광암%간기희수감%간우소
Bladdercancer%Hydroxycamptochecine%Interferon
目的 评价羟基喜树碱加干扰素灌注预防表浅性膀胱癌术后复发的疗效和安全性.方法 对62例表浅性膀胱癌患者行经尿道膀胱肿瘤电切,术后1周内予羟基喜树碱15 mg、干扰素α-2b(IFNα-2b)30×10~6IU+生理盐水40 ml膀胱内灌注,药物于膀胱内保留2小时,然后每周1次,连续6周,以后每月1次,连续12个月.定期做血尿常规、肝肾功能及膀胱镜检查,并记录每次膀胱灌注后的全身及局部反应.结果 62例均未见全身性药物不良反应.随访12～24个月,平均19个月.复发4例,复发率6.4%.结论 羟基喜树碱加干扰素膀胱灌注防止膀胱癌术后复发疗效满意,安全性好.
目的 評價羥基喜樹堿加榦擾素灌註預防錶淺性膀胱癌術後複髮的療效和安全性.方法 對62例錶淺性膀胱癌患者行經尿道膀胱腫瘤電切,術後1週內予羥基喜樹堿15 mg、榦擾素α-2b(IFNα-2b)30×10~6IU+生理鹽水40 ml膀胱內灌註,藥物于膀胱內保留2小時,然後每週1次,連續6週,以後每月1次,連續12箇月.定期做血尿常規、肝腎功能及膀胱鏡檢查,併記錄每次膀胱灌註後的全身及跼部反應.結果 62例均未見全身性藥物不良反應.隨訪12～24箇月,平均19箇月.複髮4例,複髮率6.4%.結論 羥基喜樹堿加榦擾素膀胱灌註防止膀胱癌術後複髮療效滿意,安全性好.
목적 평개간기희수감가간우소관주예방표천성방광암술후복발적료효화안전성.방법 대62례표천성방광암환자행경뇨도방광종류전절,술후1주내여간기희수감15 mg、간우소α-2b(IFNα-2b)30×10~6IU+생리염수40 ml방광내관주,약물우방광내보류2소시,연후매주1차,련속6주,이후매월1차,련속12개월.정기주혈뇨상규、간신공능급방광경검사,병기록매차방광관주후적전신급국부반응.결과 62례균미견전신성약물불량반응.수방12～24개월,평균19개월.복발4례,복발솔6.4%.결론 간기희수감가간우소방광관주방지방광암술후복발료효만의,안전성호.
Objective To evaluate intravesical instillation of Hydroxycamptochecine combined with interferon for prevention of postoperative recurrence of bladder cancer. Methods Sixty-two superficial bladder cases of TURP were treated with intravesical instillation of 15 mg hydroxycamptochecine combined 30×10~6 IU interferon dissolved in 40 ml normal saline. The drugs were retained in bladder for 2 hours. The drugs were given to bladder cancer patients postoperatively once a week for 6 weeks and subsequently once a month for 12 months. Kidney and liver function, blood counting, urinalysis and cystoscopy were taken periodically. The systemic and local reactions were recorded every time after the intravesical instillation.Results All of the 62 cases were followed up for 12 to 24 months with a mean of 19 months. The recurrence rate was 6.4%. There was no side effect. ConclusionsIntravesical instillation of Hydroxycamptochecine combined with interferon was effective for the prevention of postoperative recurrence of superficial bladder cancer with safety.
